Expired activity
Please go to the PowerPak homepage and select a course.

Type 1 Gaucher Disease: Optimizing Treatment and Management Approaches

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Genzyme, a Sanofi Company.


Lisa Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor
Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT


Dr. Holle has disclosed that she has received a grant/research support from the International Society of Oncology Pharmacy Practitioners.

The clinical reviewer, Michele A. Faulkner, PharmD, FASHP has disclosed that she has served on the speaker’s bureau for Adamas Pharmaceuticals Inc. and Eisai Pharmaceuticals.

Susanne Batesko, RN, BSN, Gary Gyss, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-19-011-H01-P
Credits: 2.0 hour (0.2 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 120 minutes


February 26, 2019

Last reviewed

November 14, 2019 (No Updates)


February 26, 2020


This accredited activity has been designed for specialty, managed care, and other pharmacists who manage or interact with patients with Gaucher disease.


During the period February 26, 2019 through February 26, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this education program is to inform managed care and specialty pharmacists on 1) epidemiology, pathophysiology, and signs and symptoms of Gaucher disease, 2) the available treatment options for type 1 Gaucher disease, specifically enzyme replacement therapies and substrate reduction therapies, 3) the efficacy, safety, and administration of available pharmacologic treatment options, and 4) the general treatment approach and management strategies for a patient with type 1 Gaucher disease.


Upon completion of this program, participants should be better able to:

  1. Discuss the background of the disease state, including pathophysiology, epidemiology, and signs and symptoms of disease
  2. Explain treatment options for type 1 Gaucher disease, including mechanisms of action and availability
  3. Evaluate the efficacy, safety, and administration of enzyme replacement therapies and substrate reduction therapies
  4. Employ strategies to effectively manage patients with type 1 Gaucher disease

*Click here to Download: Point of Care Reference Tool (PDF)


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Genzyme, Sanofi Company. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.